NASDAQ : TSHA
Taysha Gene Therapies, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 4.22 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.38B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.30B |
| Enterprise Value | 898.12M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 325.83M |
| Shares Outstanding | 325.83M |
| Shares Change (YoY) | +31.09% |
| Shares Change (QoQ) | +0.66% |
| Owned by Insiders (%) | 8.07% |
| Owned by Institutions (%) | 73.34% |
| Float | 232.62M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 241.18 |
| Forward PS | 424.25 |
| PB Ratio | 3.47 |
| P/TBV Ratio | 3.42 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 168.49 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 17.76 |
| Quick Ratio | 17.53 |
| Debt / Equity | 0.15 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3,646.64 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -47.05% |
| Return on Assets (ROA) | -23.82% |
| Return on Invested Capital (ROIC) | -25.44% |
| Return on Capital Employed (ROCE) | -34.46% |
| Weighted Average Cost of Capital (WACC) | 10.26% |
| Revenue Per Employee | $55,404 |
| Profits Per Employee | -$1.51M |
| Employee Count | 99 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.17 |
| 52-Week Price Change | -19.56% |
| 50-Day Moving Average | 4.78 |
| 200-Day Moving Average | 5.32 |
| Relative Strength Index (RSI) | 40.24 |
| Average Volume (20 Days) | 3,916,715 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 51.25M |
| Short Previous Month | 55.02M |
| Short % of Shares Out | 15.73% |
| Short % of Float | 22.03% |
| Short Ratio (days to cover) | 10.79 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 5.49M |
| Gross Profit | 5.49M |
| Operating Income | -153.16M |
| Pretax Income | -149.63M |
| Net Income | -149.63M |
| EBITDA | -151.99M |
| EBIT | -153.16M |
| Loss Per Share | -$0.41 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 455.41M |
| Total Debt | 56.71M |
| Net Cash | 398.69M |
| Net Cash Per Share | $1.22 |
| Equity (Book Value) | 387.27M |
| Book Value Per Share | 1.19 |
| Working Capital | 435.46M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -132.19M |
| Capital Expenditures | -381,000 |
| Depreciation & Amortization | 1.17M |
| Net Borrowing | 9.24M |
| Free Cash Flow | -132.57M |
| FCF Per Share | -$0.41 |
Margins
| Measure | Value |
|---|
| Gross Margin | 100.00% |
| Operating Margin | -2,792.32% |
| Pretax Margin | -2,728.04% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -31.09% |
| Shareholder Yield | -31.09% |
| Earnings Yield | -10.39% |
| FCF Yield | -10.02% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $13.00 |
| Price Target Difference | 226.63% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (3Y) | 149.69% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 6.81 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |